CSBT.F Stock Overview
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Kuros Biosciences AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF9.05 |
| 52 Week High | CHF9.05 |
| 52 Week Low | CHF2.13 |
| Beta | 0.91 |
| 1 Month Change | 50.83% |
| 3 Month Change | 78.15% |
| 1 Year Change | n/a |
| 3 Year Change | 285.11% |
| 5 Year Change | 252.14% |
| Change since IPO | 2,819.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| CSBT.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 13.6% | -2.5% | -3.2% |
| 1Y | n/a | -3.7% | 19.3% |
Return vs Industry: Insufficient data to determine how CSBT.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how CSBT.F performed against the US Market.
Price Volatility
| CSBT.F volatility | |
|---|---|
| CSBT.F Average Weekly Movement | 13.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CSBT.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CSBT.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 80 | Chris Fair | www.kuros.ch |
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through three segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold use to fill bony voids for a predictable fusion; MagnetOs Easypack Putty, a ready-to-use mold to be implanted in any intervertebral disc space or posterolateral spine level; and Magnetos Flex Matrix, an open matrix bone graft.
Kuros Biosciences AG Fundamentals Summary
| CSBT.F fundamental statistics | |
|---|---|
| Market cap | US$287.36m |
| Earnings (TTM) | -US$15.06m |
| Revenue (TTM) | US$36.81m |
8.9x
P/S Ratio-21.8x
P/E RatioIs CSBT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CSBT.F income statement (TTM) | |
|---|---|
| Revenue | CHF33.56m |
| Cost of Revenue | CHF10.69m |
| Gross Profit | CHF22.87m |
| Other Expenses | CHF36.60m |
| Earnings | -CHF13.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.37 |
| Gross Margin | 68.14% |
| Net Profit Margin | -40.90% |
| Debt/Equity Ratio | 0% |
How did CSBT.F perform over the long term?
See historical performance and comparison